Logotype for VistaGen Therapeutics Inc

VistaGen Therapeutics (VTGN) Q2 2027 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for VistaGen Therapeutics Inc

Q2 2027 earnings summary

13 Nov, 2026

Executive summary

  • Q2 net loss narrowed YoY to $10.7M from $19.4M; six-month net loss was $23.8M vs. $34.5M. Cash, cash equivalents and marketable securities totaled $20.0M at Sept. 30, 2026.

  • Substantial doubt exists about the ability to continue as a going concern; available resources are expected to fund operations into 2027, but not for at least 12 months from the report date.

  • FDA feedback clarified potential fasedienol Phase 3 pathways, with planned development aimed at treating overall SAD in the general population, subject to funding.

Financial highlights

  • Q2 revenue was $138K vs. $258K YoY; six-month revenue was $1.614M vs. $502K, including $1.3M recognized after the Fuji Pharma negotiation period ended.

  • Q2 operating expenses were $11.1M vs. $20.3M YoY, including R&D expense of $6.6M vs. $15.9M; six-month expenses were $25.9M vs. $36.4M, mainly reflecting lower R&D spending.

  • Q2 operating loss was $10.9M vs. $20.1M YoY; six-month operating loss was $24.3M vs. $35.9M. Loss per share was $0.24 and $0.54, respectively, vs. $0.54 and $1.02.

  • Q2 G&A expense was $4.5M vs. $4.4M YoY.

  • Six-month operating cash use was $26.9M vs. $32.6M; cash and cash equivalents declined to $10.9M from $30.8M at March 31, 2026.

Outlook and guidance

  • Remaining AffaMed deferred revenue of $0.1M is expected to be recognized during the rest of FY2027; absent milestones or similar deals, future sublicense revenue is expected to be substantially lower than the current six-month amount.

  • Phase 3 planning will incorporate FDA recommendations, including LSAS as the primary endpoint and interim eDiary and patient-survey assessments; FDA feedback does not assure a registrational pathway.

  • R&D expense is expected to decline further after the October workforce reduction, partly offset by ~$1.0M in severance costs in the December 2026 quarter; future spending depends on funding a new fasedienol Phase 3 trial.

  • The October workforce reduction is expected to lower annual salary and benefit costs by ~$3.2M; existing resources are insufficient for another fasedienol Phase 3 trial or further pherine development.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from VistaGen Therapeutics